Welcome to our dedicated page for DAXOR SEC filings (Ticker: DXR), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Daxor Corp’s SEC disclosures hold the clues investors crave—from FDA progress on its BVA-100 Blood Volume Analyzer to the cash burn behind ongoing clinical studies. If you have ever typed “Daxor insider trading Form 4 transactions” or wondered how to read the next “Daxor quarterly earnings report 10-Q filing,” you are in the right place. Our AI instantly sorts every exhibit, table and footnote so you can spot fluid-management milestones without scanning hundreds of pages.
Use Stock Titan to move directly to the form that answers your question:
- Need real-time alerts on “Daxor Form 4 insider transactions real-time” or “Daxor executive stock transactions Form 4”? We flag buys and sells the moment they hit EDGAR.
- Searching for “Daxor annual report 10-K simplified” or a detailed “Daxor earnings report filing analysis”? Our summaries break down R&D outlays, hospital adoption metrics and patent updates in plain English.
- Trying to compare pay packages? The platform links the “Daxor proxy statement executive compensation” sections to revenue targets tied to BVA-100 sales.
Every filing arrives within seconds, from routine 10-Qs to urgent 8-Ks—so “Daxor 8-K material events explained” is not just a headline, it’s a one-click reality. The result: “Daxor SEC filings explained simply.” Whether you’re “understanding Daxor SEC documents with AI,” monitoring cash runway between production batches, or validating management’s market forecasts, Stock Titan converts dense language into actionable insight. Stop scrolling, start learning.
Daxor (DXR) filed a routine Form 4 disclosing that director Henry D. Cremisi received an option grant for 2,500 common-stock shares on June 24 2025 under the company’s 2020 Incentive Compensation Plan, contingent upon SEC approval of an amendment to that plan. The options carry a $9.29 exercise price and vest in three annual tranches (833/883/834 shares through 2027). No DXR shares were bought or sold, and Cremisi’s beneficial ownership now includes the new grant. The filing does not report any other transactions or material changes.
Daxor – DXR filed a Form 4 reporting that director Edward Feuer was granted 2,500 stock options on 24 June 2025 at an exercise price of $9.29. The award is contingent on SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan.
The options vest in three tranches—833 on 24 Jun 2025, 883 on 24 Jun 2026 and 834 on 24 Jun 2027—and expire on 24 Jun 2030. No common shares were bought or sold, and beneficial ownership remains solely derivative. The filing represents routine equity compensation rather than an open-market transaction.
Daxor (NASDAQ:DXR) filed a Form 4 reporting the grant of 2,500 non-qualified stock options to director Joy S. Goudie on June 24 2025 at an exercise price of $9.29 per share, expiring June 24 2030.
The award is contingent upon SEC approval of an amendment to the company’s 2020 Incentive Compensation Plan and vests in three tranches: 833 options on June 24 2025, 883 on June 24 2026, and 834 on June 24 2027. No open-market purchases or sales were disclosed; the filing solely records the new derivative position. Following the transaction, Goudie beneficially owns 2,500 options with no change to her reported direct share ownership.
FAQ
What is the current stock price of DAXOR (DXR)?
What is the market cap of DAXOR (DXR)?
What is the core business of Daxor Corp?
How does the BVA-100 differentiate itself from traditional tests?
What clinical benefits does accurate blood volume measurement provide?
How is Daxor Corp positioned in the medical instrumentation industry?
What are the key features of Daxor Corp's diagnostic technology?
How does Daxor Corp ensure the reliability of its diagnostic instruments?
What challenges does Daxor Corp address with its technology?
In what ways does Daxor Corp maintain its competitive edge?
